Literature DB >> 10726375

[Fatal infectious mononucleosis during azathioprine treatment in Crohn's disease].

A Garrido Serrano1, F Pérez Martín, F J Guerrero Igea, J Galbarro Muñoz, S Palomo Gil.   

Abstract

The benefits of immunosuppressive agents in inflammatory bowel disease have been the subject of controversy. However, extensive clinical data have conclusively proved their efficacy with respect to potential toxicity. Azathioprine is one of the most widely used immunosuppressive agents in the treatment of Crohn's disease and its effectiveness has been proved in corticosteroid dependent, corticosteroid-refractory and fistulizing Crohn's disease. We present a 24-year-old male, treated with azathioprine for corticosteroid dependent Crohn's disease who was admitted to hospital with constant fever, lymphadenopathy and liver function abnormalities secondary to infectious mononucleosis after a primary infection with Epstein-Barr virus. The patient developed constitutional symptoms and progressive jaundice and 14 days after hospital admission died because of massive upper gastrointestinal bleeding due to hemorrhagic erosive gastropathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726375

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  3 in total

Review 1.  Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Christopher M Johnson; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2018-09-28

2.  Prevention of infection caused by immunosuppressive drugs in gastroenterology.

Authors:  Katarzyna Orlicka; Eleanor Barnes; Emma L Culver
Journal:  Ther Adv Chronic Dis       Date:  2013-07       Impact factor: 5.091

3.  Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn's disease.

Authors:  Y N'guyen; L Andreoletti; M Patey; C Lecoq-Lafon; P Cornillet; A Léon; R Jaussaud; C Fieschi; C Strady
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.